On September 20, 2024, the Food and Drug Administration sanctioned isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) in conjunction with bortezomib, lenalidomide, and dexamethasone for people with...
multiple-myeloma-treatment
Feb 2024: China's pioneering efforts in creating breakthrough cancer therapeutics have gained traction with the introduction of chimeric antigen receptor (CAR)-engineered T-cell (CAR T) therapy for ...
multiple-myeloma-treatment
Bone Marrow Cancer Treatment
Bone marrow cancer, or leukemia, or multiple myeloma, is a cancer of blood cells in the bone marrow that interferes with the production of normal blood cells and ...
multiple-myeloma-treatment
Plasma cell neoplasm & multiple myeloma treatment
Introduction
Plasma cell neoplasm and multiple myeloma are associated bone marrow cancers that develop from malignant plasma cells. They...
multiple-myeloma-treatment